Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
2.110
+0.070 (3.43%)
At close: Nov 21, 2024, 4:00 PM
2.102
-0.008 (-0.39%)
After-hours: Nov 21, 2024, 5:46 PM EST
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
68
Market Cap
62.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | 2.31M | 391.83K | 20.41% |
| Dec 31, 2019 | 1.92M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Procaps Group | 414.10M |
| Agenus | 160.43M |
| InterCure | 72.42M |
| Exagen | 55.75M |
| bluebird bio | 53.12M |
| Champions Oncology | 51.66M |
| VolitionRx | 1.29M |
| Entera Bio | 99.00K |
IMRX News
- 8 days ago - Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - GlobeNewsWire
- 3 months ago - Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer - GlobeNewsWire
- 6 months ago - Immuneering to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 months ago - Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 months ago - Immuneering Recognizes Melanoma Awareness Month - GlobeNewsWire
- 8 months ago - IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models - GlobeNewsWire